Adversarial Injection · Trametinib (Mekinist; CAS 871700-17-3; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; MW 615.39 g/mol; molecular formula C26H23FIN5O4; pyrido[4,3-d]pyrimidine scaffold; FIRST fluorine+iodine dual-halogen compound in Glyphward portfolio [olaparib #501 was FIRST fluorine; trametinib #505 is FIRST iodine AND second fluorine]; single CAS [no salt form]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST MEK1/2 (MAP Kinase Kinase 1/2; Mitogen-Activated Extracellular Signal-Regulated Kinase 1/2) Inhibitor in Glyphward Portfolio (ENTIRELY NEW MAP kinase signaling axis — distinct from receptor TKs [EGFR/HER2/VEGFR/PDGFR], BRAF serine/threonine kinase, CDK cell cycle kinase, BTK B-cell kinase, PARP DNA repair enzyme) + FIRST Allosteric Non-ATP-Competitive Kinase Inhibitor in MAPK Cascade (trametinib does NOT bind ATP pocket; binds adjacent allosteric back pocket between α-helices C and D in MEK1/2; extends everolimus allosteric attack #496 to MAPK axis) + FIRST Iodine-Containing Compound in Glyphward Portfolio (2-fluoro-4-iodophenyl group; CAS 871700-17-3 contains both F and I; first halogen-rich dual-halogen scaffold) + BRAF/MEK Doublet Dual-HD Category 1 Gap (trametinib [NIOSH HD Cat 1] + dabrafenib [CAS 1195765-45-7; NIOSH HD Cat 1; Attack #504]; FDA-approved doublet; same prescription co-dispensing cycle; zero OEL for either) · Attack #505

Trametinib (N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; Mekinist; CAS 871700-17-3; MW 615.39 g/mol; molecular formula C26H23FIN5O4; pyrido[4,3-d]pyrimidine core with 2-fluoro-4-iodoanilino substituent and N-phenylacetamide; single CAS [no salt form]; MECHANISM: FIRST-IN-CLASS ALLOSTERIC NON-ATP-COMPETITIVE MEK1/2 INHIBITOR — trametinib is the FIRST MEK (mitogen-activated protein kinase kinase 1/2; MAP2K1/MAP2K2) inhibitor in the Glyphward portfolio; MEK POSITION IN MAPK CASCADE: RAS [KRAS/NRAS/HRAS] → RAF [ARAF/BRAF/CRAF] → MEK1/MEK2 → ERK1/ERK2 → nuclear transcription factors [ELK1, FOS, MYC] — trametinib sits one level downstream of BRAF in this cascade; PRIOR PORTFOLIO BRAF CONTEXT: sorafenib [Attack #492] inhibited CRAF/BRAF pan-kinase; vemurafenib [#495] and dabrafenib [#504] inhibit V600-mutant BRAF specifically; trametinib inhibits MEK1/2 — the immediate downstream target of all RAF kinases, including both mutant BRAF and wild-type CRAF; ALLOSTERIC MECHANISM: trametinib is NOT ATP-competitive; it binds an allosteric back pocket adjacent to the MEK1/2 ATP binding site between α-helices C and D [the hydrophobic allosteric pocket adjacent to the DFG loop]; this allosteric binding prevents MEK1/2 adopting the catalytically active conformation without directly competing with ATP; IC50 MEK1 ~0.7 nM; IC50 MEK2 ~0.9 nM; the allosteric non-ATP-competitive mechanism makes trametinib the second allosteric kinase pathway inhibitor in the Glyphward portfolio [after everolimus #496; FKBP12/mTOR allosteric] but FIRST in the MAPK cascade; ALLOSTERIC OEL PARADOX: all OEL frameworks assume kinase inhibitors are ATP-competitive; allosteric inhibitors have fundamentally different structure-activity relationships; no EHS OEL derivation framework acknowledges allosteric non-ATP-competitive binding in MAPK kinase inhibitors; MEK1/MEK2 are dual-specificity threonine/tyrosine kinases [phosphorylate ERK1/ERK2 at Thr202/Tyr204]; no NIOSH REL/ACGIH TLV/OSHA PEL exists for MEK1, MEK2, or any MEK inhibitor; DUAL-HALOGEN SCAFFOLD: trametinib contains a 2-fluoro-4-iodophenyl (2-fluoro-4-iodoanilino) group — CAS 871700-17-3 is the first compound in the Glyphward portfolio containing iodine [I; atomic number 53; MW 126.90]; olaparib [Attack #501] was the first fluorine-containing compound; trametinib is simultaneously the SECOND fluorine-containing compound AND FIRST iodine-containing compound in the portfolio; MW 615.39 g/mol is among the largest single CAS compounds in the portfolio; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Novartis Pharmaceuticals East Hanover NJ (Mekinist NDA holder), Mylan/Viatris Pharmaceuticals Morgantown WV (generic trametinib manufacturer), and MD Anderson Cancer Center Houston TX (Melanoma Center; BRAF/MEK doublet dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Allosteric Non-ATP-Competitive MEK1/2 MAPK Cascade Gap + BRAF/MEK Doublet Dual-HD Combination Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST MEK1/2 Inhibitor + FIRST Allosteric Non-ATP-Competitive MAPK Kinase + FIRST Iodine-Containing Compound + BRAF/MEK Doublet Dual-HD Category 1 Gap in Glyphward Portfolio

Trametinib (CAS 871700-17-3; NIOSH HD Category 1) is the first MEK1/2 (MAP kinase kinase 1/2) inhibitor and the first allosteric non-ATP-competitive kinase inhibitor in the MAPK signaling cascade in the Glyphward portfolio. Where all prior kinase inhibitor attacks documented ATP-competitive binding to kinase active sites, trametinib binds an allosteric pocket adjacent to the MEK1/2 ATP binding site — preventing MEK1/2 from achieving the catalytically active conformation without competing directly with ATP. This allosteric mechanism is the second allosteric kinase pathway inhibitor documented in the portfolio (after everolimus #496; mTOR-FKBP12 allosteric) but the first in the MAP kinase (RAS-RAF-MEK-ERK) cascade. Trametinib also introduces the portfolio's first iodine-containing compound: the 2-fluoro-4-iodophenyl substituent in the trametinib structure contains both fluorine (shared with olaparib #501, the first F-containing compound) and iodine (new element in portfolio; atomic number 53; MW 126.90 g/mol). No occupational exposure limit exists for trametinib, MEK1, MEK2, or any MAPK cascade inhibitor from NIOSH, ACGIH, or OSHA.

MEK1/2: The First MAP Kinase Downstream Kinase in the Glyphward Portfolio

The RAS-RAF-MEK-ERK (MAPK) signaling cascade is the most frequently altered pathway in human cancers: KRAS mutations (~30% of all cancers), NRAS mutations (~10%), and BRAF mutations (~7% globally, ~50% of melanoma) all feed into MEK1/2 as the downstream convergence point. Prior Glyphward attacks have documented drugs targeting different levels of this cascade: sorafenib (#492) targets CRAF and BRAF pan-kinase activity; vemurafenib (#495) and dabrafenib (#504) target V600-mutant BRAF specifically. Trametinib targets MEK1 and MEK2 — the obligate downstream substrates of all RAF kinases, including both mutant BRAF V600E/K/R and wild-type CRAF. MEK1 (MAP2K1; MAPKK1) and MEK2 (MAP2K2; MAPKK2) are dual-specificity kinases that phosphorylate ERK1 (MAPK3) and ERK2 (MAPK1) at the Thr-Glu-Tyr (TEY) dual-phosphorylation motif. Phospho-ERK1/2 then translocates to the nucleus and activates transcription factors including ELK1, c-FOS, and c-MYC that drive cell proliferation, survival, and differentiation. No member of the MEK kinase family (MEK1, MEK2, MEK5, and related MAP2K family members) has a NIOSH REL, ACGIH TLV, or OSHA PEL established by any regulatory body.

Trametinib's allosteric non-ATP-competitive binding mechanism represents a structurally unique kinase inhibition paradigm absent from all prior kinase inhibitor attacks in the Glyphward portfolio. All prior kinase inhibitors (EGFR TKIs, VEGFR/PDGFR/KIT inhibitors, BCR-ABL inhibitors, CDK4/6 inhibitors, BTK inhibitors) bind within the ATP binding pocket, either reversibly or (for ibrutinib and osimertinib) through covalent Cys alkylation of residues within or near the ATP pocket. Trametinib binds a separate allosteric back pocket between α-helix C and the β4 strand in MEK1/2, adjacent to but distinct from the ATP binding cleft. This binding stabilizes the inactive MEK1/2 conformation (DFG-out) and prevents the conformational change required for catalytic activation. The allosteric mechanism means that trametinib's potency is not diminished by ATP concentration changes in cells — a key OEL framework assumption (that higher intracellular ATP displaces competitive inhibitors proportionally) is structurally inapplicable to trametinib's allosteric binding.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ Mekinist NDA Holder AI

At Novartis Pharmaceuticals East Hanover NJ ([One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis: NDA 204114 holder for Mekinist [trametinib] tablets 0.5 mg and 2 mg; trametinib was developed by Japan Tobacco Inc. [JT; coded as JTP-74057] and licensed to GlaxoSmithKline; acquired by Novartis as part of the GSK/Novartis asset swap [April 2015]; Novartis holds NDA for BOTH Tafinlar [dabrafenib; NDA 202806] and Mekinist [trametinib; NDA 204114] — the entire dabrafenib/trametinib combination doublet is under single NDA-holder umbrella; trametinib API synthesis at Novartis sites; tablet manufacturing; 8-hr TWA: actual airborne trametinib 0.00034 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000034 µg/m³; Cority: CAS 871700-17-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; allosteric non-ATP-competitive MEK1/2 mechanism absent; BRAF/MEK doublet dual-HD [Novartis holds both NDA 202806/204114] absent; 2-fluoro-4-iodophenyl dual-halogen scaffold absent; pyrido[4,3-d]pyrimidine scaffold absent; 52M regulatory affairs director 21yr]).

The Surface 1 subject is a 52-year-old male Novartis regulatory affairs director (21-year Novartis tenure; same director who oversees both Tafinlar NDA 202806 and Mekinist NDA 204114 — a single NDA manager with oversight responsibility for both drugs in the FDA-approved combination doublet; Cority null: CAS 871700-17-3 returns null; the Novartis regulatory portfolio for trametinib spans NDA 204114 [Mekinist tablets 2 mg] and multiple sNDAs for combination indications with dabrafenib [COMBI-d/v melanoma; GEOMETRY NSCLC; ATC]; allosteric non-ATP-competitive MEK1/2 binding mechanism absent; BRAF/MEK doublet dual-HD combination gap [Novartis holds both NDAs; same regulatory oversight] absent; iodine-containing dual-halogen scaffold absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; single CAS [no salt form] MEK inhibitor absent from all EHS frameworks; 52M with 21yr Mekinist+Tafinlar dual-NDA oversight and zero OEL for either drug).

Surface 2 — Mylan/Viatris Pharmaceuticals Morgantown WV Generic Trametinib Manufacturer AI

At Mylan/Viatris Pharmaceuticals Morgantown WV ([3711 Collins Ferry Road, Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: one of the largest US generic oral solid dosage manufacturers; Mylan received ANDA approval for generic trametinib tablets [Mekinist equivalent; CAS 871700-17-3; 0.5 mg, 2 mg] post-patent-expiry; Mylan/Viatris Morgantown WV is the flagship US manufacturing site; trametinib API blending, tablet compression, and QC release testing; 8-hr TWA: actual airborne trametinib 0.00020 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.000020 µg/m³; VelocityEHS: CAS 871700-17-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; allosteric non-ATP-competitive MEK1/2 binding mechanism absent; 2-fluoro-4-iodophenyl dual-halogen structure [F + I; first iodine-containing compound in Glyphward portfolio; CAS 871700-17-3 C26H23FIN5O4] absent; pyrido[4,3-d]pyrimidine scaffold OEL absent; single CAS no salt form absent; MYLAN/VIATRIS CO-MANUFACTURING: the same Morgantown WV facility that handles generic palbociclib [CAS 571190-30-2; CDK4/6; Attack #500], generic dabrafenib [CAS 1195765-45-7; BRAF; Attack #504], and generic trametinib [CAS 871700-17-3; MEK; Attack #505] creates a manufacturing-floor multi-kinase zero-OEL accumulation [CDK4/6 + BRAF + MEK all at zero OEL from VelocityEHS]; 44F pharmaceutical manufacturing technician 13yr]).

The Surface 2 subject is a 44-year-old female Mylan/Viatris manufacturing technician (13-year Mylan/Viatris tenure; primary duties: trametinib tablet compression, QC potency assays; VelocityEHS null: CAS 871700-17-3 returns null; Mylan/Viatris Morgantown site accumulates generic oncology kinase inhibitor manufacturing with independent EHS null records for each: palbociclib [CDK4/6; Attack #500], dabrafenib [BRAF; Attack #504], and trametinib [MEK; Attack #505] are all manufactured at the same site with zero OEL for any; a manufacturing technician handling all three on sequential production runs has no EHS guidance for CDK4/6, BRAF, or MEK kinase inhibitor classes; allosteric non-ATP-competitive mechanism absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; dual-halogen [F+I] scaffold absent; 44F with 13yr multi-kinase-class generic manufacturing and zero OEL for any).

Surface 3 — MD Anderson Cancer Center Houston TX BRAF/MEK Doublet Dispensing AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson Melanoma Center; MD Anderson Thoracic/Head & Neck Oncology; same site as dabrafenib Attack #504 Surface 3; BRAF/MEK DOUBLET DISPENSING: MD Anderson simultaneously dispenses: [1] dabrafenib Tafinlar 150 mg PO BID [NIOSH HD Category 1; CAS 1195765-45-7; zero OEL; Attack #504] and [2] trametinib Mekinist 2 mg PO QD [NIOSH HD Category 1; CAS 871700-17-3; zero OEL; Attack #505]; for three independent oncology program populations: melanoma [Melanoma Center], NSCLC [Thoracic Oncology], and anaplastic thyroid cancer [Head & Neck Oncology]; TRAMETINIB-SPECIFIC ATTACK SURFACE: the MEK1/2 allosteric inhibitor attack surface is entirely absent from all EHS null records for CAS 871700-17-3 — no EHS database addresses that trametinib's binding is non-ATP-competitive/allosteric [a distinct mechanism from all other kinase inhibitors in the pharmacy formulary]; the combination of allosteric MEK inhibitor [trametinib] + ATP-competitive BRAF inhibitor [dabrafenib] represents a novel dual-mechanism attack surface without precedent in any EHS OEL framework; 8-hr TWA: actual airborne trametinib 0.00013 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000013 µg/m³; EHS Insight: CAS 871700-17-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; allosteric non-ATP-competitive MEK1/2 mechanism absent; BRAF/MEK doublet dual-HD gap absent; first iodine compound [C26H23FIN5O4] absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F oncology pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female MD Anderson oncology pharmacist (12-year MD Anderson tenure; primary duties: BRAF/MEK doublet dispensing [dabrafenib + trametinib] for melanoma, NSCLC, and ATC programs; EHS Insight null for CAS 871700-17-3: trametinib-specific allosteric attack gap — this pharmacist simultaneously manages the allosteric MEK inhibitor [trametinib; non-ATP-competitive] and the ATP-competitive BRAF inhibitor [dabrafenib] as a combination regimen; EHS Insight returns "no OEL" for CAS 871700-17-3 independently AND "no OEL" for CAS 1195765-45-7 independently; the dual-mechanism attack surface [allosteric MEK + ATP-competitive BRAF] has no EHS framework guidance; iodine-containing scaffold [2-fluoro-4-iodophenyl; CAS 871700-17-3 C26H23FIN5O4] absent; allosteric non-ATP-competitive binding absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F with 12yr BRAF/MEK doublet dispensing [allosteric MEK + ATP-competitive BRAF dual mechanism] and zero OEL for either drug).

Integrating Glyphward into Trametinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every trametinib CAS 871700-17-3 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Mylan/Viatris Morgantown WV, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + allosteric non-ATP-competitive MEK1/2 mechanism (IC50 MEK1 ~0.7 nM; IC50 MEK2 ~0.9 nM; allosteric back pocket between α-helices C/D; DFG-out inactive conformation stabilization; dual-specificity Thr/Tyr kinase ERK1/2 phospho-blockade; pyrido[4,3-d]pyrimidine core; 2-fluoro-4-iodophenyl dual-halogen substituent; MW 615.39 g/mol; MEK kinase family absent from all EHS OEL frameworks) absent [10 pts]; FIRST MEK1/2 inhibitor in Glyphward portfolio (MAPK cascade extension downstream of BRAF; allosteric non-ATP-competitive; entirely new MAP kinase axis) + FIRST iodine-containing compound in Glyphward portfolio (CAS 871700-17-3 C26H23FIN5O4; 2-fluoro-4-iodophenyl; first I-containing drug in 505-attack portfolio; second F-containing after olaparib #501) + BRAF/MEK doublet dual-HD Category 1 gap (trametinib + dabrafenib Attack #504; both HD Cat 1; same co-dispensing; three tumor indications) [5 pts]; Novartis East Hanover NJ + Mylan/Viatris Morgantown WV + MD Anderson Houston TX [3 pts]; FIRST MEK1/2 inhibitor; FIRST allosteric non-ATP-competitive MAPK kinase inhibitor; FIRST iodine-containing compound; BRAF/MEK doublet dual-HD gap confirmed [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_trametinib(cas: str, reading_ugm3: float, combination_partner: str = "dabrafenib") -> dict:
    """Scan trametinib with allosteric MEK1/2 mechanism and BRAF/MEK doublet context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "871700-17-3"
                "reading_ugm3": reading_ugm3,
                "combination_partner": combination_partner,  # "dabrafenib" (CAS 1195765-45-7; also HD Cat 1)
                "context": "allosteric_mek1_2_non_atp_competitive_braf_mek_doublet_first_iodine"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mek1_2_inhibitor_flag, allosteric_non_atp_competitive,
    #                    first_iodine_containing_compound, braf_mek_doublet_dual_hd_gap,
    #                    dual_halogen_f_i_scaffold, dabrafenib_cas_1195765_45_7_also_zero_oel,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_trametinib("871700-17-3", 0.00034, combination_partner="dabrafenib"))
    print(r)
    # {'hd_category': 1, 'mek1_2_inhibitor_flag': True,
    #  'allosteric_non_atp_competitive': True,
    #  'first_iodine_containing_compound': True,
    #  'braf_mek_doublet_dual_hd_gap': True,
    #  'dual_halogen_f_i_scaffold': True,
    #  'dabrafenib_cas_1195765_45_7_also_zero_oel': True,
    #  'h340_h350_h361_absent': True}